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ABSTRACT
Increased export of transglutaminase-2 (TG2) by tubular epithelial cells (TECs) into the surrounding interstitium
modiﬁes the extracellular homeostatic balance, leading to ﬁbrotic membrane expansion. Although silencing of
extracellular TG2 ameliorates progressive kidney scarring in animal models of CKD, the pathway through which
TG2 is secreted from TECs and contributes to disease progression has not been elucidated. In this study, we
developed aglobal proteomic approach to identify bindingpartners of TG2 responsible for TG2externalization in
kidneys subjected to unilateral ureteric obstruction (UUO) using TG2 knockout kidneys as negative controls. We
report a robust andunbiasedanalysis of themembrane interactomeofTG2 inﬁbrotic kidneys relative to theentire
proteomeafterUUO, detectedby SWATHmass spectrometry. Thedata havebeendeposited to theProteomeX-
change with identiﬁer PXD008173. Clusters of exosomal proteins in the TG2 interactome supported the hypoth-
esis that TG2 is secreted by extracellular membrane vesicles during ﬁbrosis progression. In established TEC lines,
we foundTG2 in vesicles of both endosomal (exosomes) andplasmamembraneorigin (microvesicles/ectosomes),
and TGF-b1 stimulated TG2 secretion. Knockout of syndecan-4 (SDC4) greatly impaired TG2 exosomal secretion.
TG2 coprecipitated with SDC4 from exosome lysate but not ectosome lysate. Ex vivo, EGFP-tagged TG2 accu-
mulated in globular elements (blebs) protruding/retracting from the plasma membrane of primary cortical TECs,
and SDC4 knockout impaired bleb formation, affecting TG2 release. Through this combined in vivo and in vitro
approach, we have dissected the pathway through which TG2 is secreted from TECs in CKD.
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Fibrotic remodeling is the primary pathologic process
associated with progressive CKD leading to end stage
renal disease.1,2 Increased synthesis and especially, ex-
ternalization of protein crosslinking enzyme transglu-
taminase-2 (TG2) by cortical tubular epithelial cells
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Signiﬁcance Statement
Secretion of the matrix crosslinking enzyme transglu-
taminase-2 (TG2) from tubular epithelial cells has been
shown to contribute to ﬁbrotic remodeling, a primary
pathologic process in CKD. To discover the pathway for
secretionofTG2, a comparativeproteomic strategywas
developed. Proteins that interact with TG2 were iden-
tiﬁed by TG2 immunoprecipitation from wild-type and
TG2 knockout ﬁbrotic kidney membranes followed by
SWATH mass spectroscopy. The TG2 interactome was
enriched in extracellular vesicle proteins, suggesting
that TG2 is secreted in exosomes. Studies in cultured
tubular epithelial cells support this conclusion and
suggest that TG2 is a binding cargo of syndecan-4. The
ﬁnding of TG2 in the urine of patients with CKD raises
the possibility that block of vesicular TG2 could reduce
TG2-driven matrix accumulation and diminish ﬁbrosis.
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(TECs) into the surrounding interstitium are signiﬁcant features of
progressive kidney scarring.3–5 TG2 is the most widespread mem-
ber of a family ofCa2+-dependent enzymes, and it is able to catalyze
an acyl transfer reaction between peptide-bound glutamine res-
idues and peptide-bound lysine residues, leading to the post-
translational modiﬁcation of proteins through the formation of
intra- or intermolecular N«(g-glutamyl)lysine bonds. After it is
outside the cell, TG2 accelerates the deposition of available extra-
cellular matrix (ECM) substrates and confers ECM resistance to
proteases.4 Furthermore, TG2 enhances TGF-b activation,6–8 the
prototypical proﬁbrotic cytokine in CKD.9 Inhibition of extracel-
lularTG2activity10,11 or knockout (KO)of theheparan sulfate (HS)
proteoglycan syndecan-4 (SDC4),12 which is responsible for TG2
extracellular trafﬁcking through an undiscovered mechanism,13
ameliorates kidney ﬁbrosis in experimental models of CKD.
Despite a link between externalization of
TG2and tubulointerstitialﬁbrosis that iswell
established,10 the pathway through which
TG2 is secreted from TECs, a major source
of TG2 in CKD,4 has not been fully eluci-
dated, because TG2 lacks the leader peptide
for the classic endoplasmic reticulum-Golgi
secretory pathway. PreliminaryworkonTG2
release by TECs has suggested that an intact
ﬁbronectin (FN)-binding N-terminal
b-sandwich domain is crucial for TG2 secre-
tion but that the extracellular trafﬁcking of
TG2 is independent of FN.14 Alternative
secretory pathways have been proposed,15
either investigated in transfected NIH3T3
ﬁbroblasts involving TG2 loading into recy-
cling endosomes at the perinuclear recy-
cling compartment, small Rab11 GTPase
activity, and binding to endosomal phos-
phoinositides16 or in transfected HEK293
cells involving opening of a purinergic
P2X7 receptor-dependent membrane
pore.17 Furthermore, we know that the as-
sociation of TG2 with the HS proteoglycan
SDC4 favors the enzyme secretion inmouse
dermal ﬁbroblasts13 and in vivo.12
With the aim of unraveling the mecha-
nismof TG2 secretion inCKD, in this study,
we report a comprehensive and unbiased
analysis of the membrane interactome of
TG2 in kidneys subjected to unilateral ure-
teric obstruction (UUO). An enrichment of
extracellular vesicle (EV)proteinswas iden-
tiﬁed in TG2 membrane complexes. This
formed the hypothesis of an EV-dependent
secretion for TG2. This hypothesis was
tested in established TEC lines and primary
TECs. Our ﬁndings suggest, for the ﬁrst
time, a pathway through which TG2 is se-
creted from TECs and reveal the involve-
ment of SDC4 in CKD pathogenesis.
RESULTS
Quantitative Proteomic Approach for the Analysis of
TG2 Interactome in UUO Kidneys
Induction of renal ﬁbrosis was performed in wild type (WT)
and TG2-KO animals. TG22/2 and TG2+/+ inbred C57BL/6J
mice were subjected to UUO of the left kidney or a sham
operation, and kidneys were harvested at 21 days postsurgery.
WT UUO kidneys were positive to a-smooth muscle actin
(Figure 1A), displayed a signiﬁcantly higher level of active
TGF-b (mink lung epithelial cell assay) (Figure 1B), and
showed increased collagen deposition in the interstitium and
Figure 1. A UUO model in WT and TG2 KO kidneys shows that absence of TG2 re-
duces the development of experimental ﬁbrosis. TG2 KO and WT mice were sub-
jected to UUO or a sham operation. (A) Western blot analyses for the expression of
TG2, a-SMA, and cyclophilin-A (PPIA; loading control) in the obstructed kidneys (21
days). Data represent mean band intensities normalized to PPIA relative to the WT
sham-operated control (equalized to one) 6SEM; n=3 kidney lysates per group. (B)
Active and total TGF-b quantiﬁed via the mink lung epithelial cell bioassay. Data
represent the ratio of active TGF-b to total TGF-b expressed relative to the WT sham-
operated control (equalized to one) 6SEM; n=3 kidney lysates per group. (C) Repre-
sentative micrographs of Masson’s trichrome staining; scarring index was determined
as the ratio of collagen staining (light blue) over cytoplasmic staining (pink). Data
represent mean values relative to the WT sham (equalized to one) 6SEM; n=24
nonoverlapping ﬁelds per treatment covering tubular and glomerular areas. Mag-
niﬁcation, 320. *P,0.05; **P,0.01; ***P,0.01; ****P,0.001.
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periglomerulus (Figure 1C). Notably, TG2-null UUO kidneys
had a lower level of a-smooth muscle actin (Figure 1A) and
active TGF-b (Figure 1B). Moreover, TG2-null kidneys
displayed a reduced level of collagen deposition as conﬁrmed
by image analysis (Figure 1C). These data reveal that TG2
expression is important in ﬁbrosis develop-
ment post-UUO, because the disease de-
velops more slowly if TG2 is absent from
the extracellular environment.
To identify protein partners of TG2 in
the murine UUOmodel of CKD (the “TG2
interactome”), we combined TG2 immu-
noprecipitation (IP) from whole-kidney
membrane preparations of WT and TG2-
null kidneys, sham and UUO, with
quantitative proteomics by sequential win-
dow acquisition of all theoretical fragment
ion spectra (SWATH) mass spectrometry
(MS).18 The TG2 IP proteome from the
TG2 KOwas subtracted from the respective
TG2 IP WT proteome to reveal only the
TG2-dependent interactions. An outline
of this original approach is shown in Figure
2A. Cytosol and membrane fractions from
WTand TG2 KO kidneys were validated by
detection of Na+/K+ ATPase, which was
solely displayed by the membrane lysate,
and b-tubulin, which was present in both
fractions (Figure 2B). TG2-associated
complexes were isolated by IP using mag-
netic beads coated with anti-TG2 antibody.
Western blotting conﬁrmed the presence of
TG2 inWT fractions (Figure 2B); addition-
ally, SDS-PAGE followed by Coomassie
blue staining revealed the presence of
TG2-associated proteins in the membrane
lysate of WT kidneys immunoprecipitated
with anti-TG2 antibody and a very low level
of proteins in TG2-null kidneys processed
in the same way (Figure 2C). Proteins re-
cruited by the anti-TG2 antibody beads
were analyzed by quantitative proteomics.
We used SWATHacquisitionMS18 to resolve
proteomes at the highest possible sensitiv-
ity, reproducibility, and proteome cover-
age. To avoid bias from individual donors
and achieve generalizable results, we per-
formed ﬁve independent IP experiments,
each on the basis of lysates generated
from two animal donors, and a sixth IP
to build the spectral library as outlined in
Figure 2D; we used only malemice to avoid
any sex/hormonal bias. Differences be-
tween WT and TG2-null precipitated pro-
teins (representing the background) were
established by a paired sample z test after analysis by SWATH
processing (Figure 2, A and D, Supplemental Material). In this
way, we could distinguish TG2-dependent protein recruit-
ment from nonspeciﬁc background. However, not all of the
TG2-associated proteins were expected to be directly bound to
Figure 2. A comparative proteomic approach for the analysis of TG2 interactome in
kidney ﬁbrotic membranes. (A) Workﬂow of the strategy for the isolation of TG2-
interacting proteins. TG2 was immunoprecipitated from kidney membrane fractions
obtained from WT and TG2-null kidneys (used as negative controls). TG2-associated
proteins were isolated by IP using a monoclonal anti-TG2 antibody (IA12) crosslinked
to magnetic beads. The TG2 coimmunoprecipitates (TG2 IP) were proteolytically
digested directly on beads and analyzed via SWATH acquisition MS. Five TG2 IP
samples per treatment were analyzed by data-independent acquisition (DIA) using
34 static SWATH windows of m/z 15. A spectral library, produced by shotgun/data-
dependent acquisition (DDA) MS on a pool of all samples, was used for extracting
the SWATH quantitative data. Differences between WT and TG2 KO precipitated
proteins (representing the background) were identiﬁed by a paired sample z test,
leading to the TG2 interactome. (B) Kidney fractions (membrane [M] and cytosolic
[C]) were validated by Western blotting for enrichment of membrane marker (Na+/K+
ATPase) or tubulin. TG2 was detected in Western blots of the fractions before and
after TG2 IP. (C) Coomassie staining of TG2 immunoprecipitates separated by SDS-
PAGE. The rectangular area identiﬁes the precipitated TG2. Std. TG2, puriﬁed
guinea pig liver TG2. (D) Sample size and animal numbers (N ) used in the study; n
indicates independent experiments. (E) Number of proteins identiﬁed as speciﬁcally
associated with TG2 in UUO and sham-operated kidney membranes by z test
(P#0.05; n$4) after exclusion of nuclear, mitochondrial, and ribosomal proteins.
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Table 1. Speciﬁc TG2 partner proteins in the UUO kidney (membrane fraction)
Identiﬁcation Name n P Value U/S
DESP Desmoplakin 5 1.22E213 U
HSP7C Heat shock cognate 71-kD protein 5 7.67E210 U
CALM Calmodulin 5 1.83E208 U/S
CAZA2 F-actin–capping protein subunit-a2 5 1.97E208 U
GPX1 Glutathione peroxidase 1 5 4.52E207 U
ADH1 Alcohol dehydrogenase 1 5 9.40E207 U/S
POSTN Periostin 4 1.03E206 U
MYO1D Unconventional myosin-Id 5 3.52E206 U
GLRX1 Glutaredoxin-1 4 5.61E206 U
GLRX3 Glutaredoxin-3 5 1.40E205 U
PROF1 Proﬁlin-1 5 1.89E205 U
TGM2 Transglutaminase 2 5 3.31E205 U/S
HSPB1 Heat shock protein-b1 5 3.68E205 U
VATH V-type proton ATPase subunit H 5 5.98E205 U
ADDG g-Adducin 5 6.66E205 U
AT2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 5 8.58E205 U
SVIL Supervillin 4 1.01E204 U
COR1C Coronin-1C 5 1.38E204 U
IQGA1 Ras GTPase-activating–like protein IQGAP1 5 1.50E204 U/S
TCPE T-complex protein 1 5 3.17E204 U
UBP5 Ubiquitin C-terminal hydrolase 5 5 4.59E204 U
FLOT2 Flotillin-2 4 5.38E204 U
NAMPT Nicotinamide phosphoribosyltransferase 5 6.56E204 U/S
PCKGC Phosphoenolpyruvate carboxykinase 5 8.93E204 U/S
RAB1A Ras-related protein Rab-1A 5 9.16E204 U
SDC4 Syndecan-4 5 9.34E204 U
LDHA L-lactate dehydrogenase A chain 4 1.04E203 U
MYO1G Unconventional myosin-Ig 5 1.21E203 U
K1C20 Keratin, type I cytoskeletal 20 4 1.35E203 U
COEA1 Collagen-a1(XIV) chain 5 1.64E203 U
COCA1 Collagen-a1(XII) chain 4 1.68E203 U
HIP1 Huntingtin-interacting protein 1 4 1.86E203 U
LIMS1 LIM and senescent cell antigen-like–containing domain protein 1 5 2.47E203 U/S
SAR1B GTP binding protein SAR1b 5 2.79E203 U
SPTA1 Spectrin a-chain, erythrocytic 1 5 2.92E203 U/S
FLNA Filamin-A 5 2.98E203 U
ANK3 Ankyrin-3 5 3.03E203 U
PSD11 26S proteasome non-ATPase regulatory subunit 11 5 3.09E203 U
PGBM Basement membrane–speciﬁc heparan sulfate proteoglycan core protein (Perlecan) 5 3.16E203 U
LSP1 Lymphocyte-speciﬁc protein 1 5 3.53E203 U
GELS Gelsolin 5 4.61E203 U
YKT6 Synaptobrevin homolog YKT6 5 4.72E203 U
PTN6 Tyrosine-protein phosphatase nonreceptor type 6 4 4.84E203 U/S
FLNB Filamin-B 5 5.03E203 U
TLN2 Talin-2 5 5.28E203 U
PGK1 Phosphoglycerate kinase 1 4 5.39E203 U/S
PICAL Phosphatidylinositol binding clathrin assembly protein 4 5.65E203 U/S
F120A Constitutive coactivator of PPARg-like protein 1 5 6.27E203 U/S
PRDX2 Peroxiredoxin-2 4 6.87E203 U/S
KCC2D Calcium/calmodulin-dependent protein kinase type II subunit-d 5 7.10E203 U
RTN4 Reticulon-4 5 7.57E203 U
SERA D-3-phosphoglycerate dehydrogenase 5 7.78E203 U/S
KC1A Casein kinase I isoform-a 5 8.06E203 U
DCTN1 Dynactin subunit 1 5 8.52E203 U
ADDA a-Adducin 5 8.61E203 U
PGS2 Decorin 5 1.09E202 U
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Table 1. Continued
Identiﬁcation Name n P Value U/S
IF4G3 Eukaryotic translation initiation factor 4-g3 5 1.11E202 U/S
RHG18 Rho GTPase-activating protein 18 4 1.11E202 U
CAPZB F-actin–capping protein subunit-b 5 1.11E202 U
MVP Major vault protein 5 1.14E202 U
TERA Transitional endoplasmic reticulum ATPase 5 1.21E202 U/S
ACTB Actin, cytoplasmic 1 5 1.24E202 U
PGS1 Biglycan 5 1.30E202 U/S
K1C14 Keratin, type I cytoskeletal 14 5 1.33E202 U
PLSL Plastin-2 5 1.34E202 U
AP2A2 AP-2 complex subunit-a2 5 1.52E202 U
FINC Fibronectin 5 1.57E202 U/S
CLCB Clathrin light-chain b 5 1.65E202 U
SNX4 Sorting nexin-4 5 1.67E202 U
SPTB1 Spectrin b-chain, erythrocytic 5 1.73E202 U
ZO1 Tight junction protein ZO-1 4 1.79E202 U
DREB Drebrin 5 1.83E202 U
CAN1 Calpain1 5 1.84E202 U
PDLI5 PDZ and LIM domain protein 5 5 1.85E202 U
PUR6 Multifunctional protein ADE2 5 1.88E202 U
MY18A Unconventional myosin-XVIIIa 5 1.93E202 U
CLCA Clathrin light-chain A 5 2.07E202 U
IRGM1 Immunity-related GTPase family M protein 1 5 2.09E202 U
NEB2 Neurabin-2 5 2.11E202 U
K2C6B Keratin, type II cytoskeletal 6B 5 2.14E202 U
AP2A1 AP-2 complex subunit-a1 5 2.15E202 U
LYPA1 Acyl-protein thioesterase 1 5 2.18E202 U
PDC6I Programmed cell death 6–interacting protein 5 2.38E202 U/S
AP2B1 AP-2 complex subunit-b 5 2.43E202 U
K1C19 Keratin, type I cytoskeletal 19 5 2.58E202 U
GRP78 78-kD Glucose-regulated protein 5 2.59E202 U
ARK72 Aﬂatoxin B1 aldehyde reductase member 2 5 2.61E202 U
SNTB2 b2-Syntrophin 5 2.63E202 U
MYO1B Unconventional myosin-Ib 5 2.67E202 U
K6PP ATP-dependent 6-phosphofructokinase, platelet type 5 2.67E202 U
C1QB Complement C1q subcomponent subunit B 5 2.71E202 U
F213A Redox-regulatory protein FAM213A 5 2.79E202 U/S
HS90A Heat shock protein HSP 90a 5 2.85E202 U
GAK Cyclin-G–associated kinase 5 2.86E202 U
SPTN1 Spectrin a-chain, nonerythrocytic 1 5 3.08E202 U/S
UCK1 Uridine-cytidine kinase 1 5 3.12E202 U
ECHP Peroxisomal bifunctional enzyme 5 3.15E202 U/S
ES8L2 EGF receptor kinase substrate 8–like protein 2 4 3.29E202 U
MOES Moesin 5 3.33E202 U
PNCB Nicotinate phosphoribosyltransferase 5 3.34E202 U
MYH10 Myosin-10 5 3.59E202 U
RBGPR Rab3 GTPase-activating protein noncatalytic subunit 5 3.65E202 U
VIME Vimentin 5 3.66E202 U
SERPH Serpin 1H 5 3.81E202 U
RPN1 Dolichyl-diphosphooligosaccharide–protein glycosyltransferase subunit 1 4 3.89E202 U
LAMB2 Laminin subunit-b2 4 3.92E202 U/S
GSTT1 Glutathione S-transferase-u1 5 3.95E202 U
TCPQ T-complex protein 1 5 3.96E202 U
TCPZ T-complex protein 1 5 4.23E202 U/S
IRAK4 IL-1 receptor-associated kinase 4 5 4.24E202 U
C1TC C-1–tetrahydrofolate synthase 5 4.28E202 U
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TG2; somemolecules could be indirect partners of TG2, bound
to its direct interactors. The complete list of 217 proteins di-
rectly or indirectly associated with TG2 in UUO (122 proteins)
or sham (120 proteins) kidney membranes, which were char-
acterized by either a plasma membrane (PM) or ECM com-
partmentalization or by a location in biologic ﬂuids, is shown
in Tables 1 and 2, respectively (P#0.05; identiﬁed in at least
four of ﬁve experiments; n$4). Original processed data with
statistical analysis are provided as Supplemental Appendix 1.
There was little overlap (11.5%) between cell matrix proteins
associated with TG2 in the normal (sham) and ﬁbrotic kidneys
(UUO) (Figure 2E). This is not surprising, because TG2 be-
comes activated in disease both in terms of export4,8 and in
terms of enzymatic activity.19,20 There was a considerable clus-
ter of proteins uniquely part of the UUO TG2 interactome
(44.7%) or exclusively associated with TG2 in the normal kid-
neys (43.8%) (Figure 2E). Membrane proteins previously re-
ported to be exclusively located in nucleus and mitochondrial
membranes were manually selected from the SWATH MS
dataset according to the subcellular localization database
“COMPARTMENTS” and UniProtKB (Supplemental Figure
1). Ribosomal proteins and Igs found in the membrane prep-
aration are shown in Supplemental Table 1.
TG2 Interaction Networks Reveal a Predominance of
Vesicular Trafﬁcking and Actin Dynamics Proteins in
the UUO Kidney
Analysis of functions obtained by UniprotKB database (Mus
musculus) revealed enrichment of TG2 interactions with proteins
involved invesicular trafﬁcking and cytoskeletal actin dynamics in
the UUO kidney (Figure 3A). Canonical TG2 partner proteins
were present (e.g., in cell adhesion, FN, SDC4, and collagens
[COCA1 and COEA1]; in cytoskeleton, actin and ﬁlamin
[FLNA and FLNB] [Figure 3B]), but there were also unexpected
absences, such as the integrin family. This may be because of the
transitory nature of integrin complexes, which can be only effec-
tively captured by stabilizing the interaction with a chemical
crosslinker.21 Desmoplakin (involved in interepithelial cell adhe-
sion), F-actin capping protein (CAZA2), and proﬁlin-1 (PROF1;
involved in actin cytoskeleton remodeling) were new highly sig-
niﬁcant partners of TG2 in UUO. Proteins that had never been
associated or connected with TG2, such as a series of vesicular
trafﬁcking proteins like clathrin and adaptor proteins (CLCA,
CLCB, AP2A1, AP2A2, and AP2B1), sorting nexins (SNX1 and
SNX4), Alix (PDC6I), ﬂotillin-2 (FLOT2), and heat shock cog-
nate 71-kD protein (HSP7C), formed a large part of the TG2
UUO interactome (Figure 3B). Moreover, redox regulation pro-
teins, such as glutathione peroxidase-1, glutaredoxin-1 (GLRX1),
and GLRX3, were signiﬁcant TG2 partners in the UUO (Figure
3B). Therewas a deﬁnite difference in the composition of theTG2
partners between the UUO and normal (sham) status, and pro-
teins associatedwithTG2uniquely in theUUOstatewere likely to
inﬂuence its trafﬁcking, activity, and regulation in ﬁbrosis.
Network analysis of the TG2 interactomes built using the
STRING v10 bioinformatics tool (on the basis of known and
predicted protein-protein interactions) showed a clear cluster
of proteins associatedwithmembrane vesicles (Figure 4A, light
blue), redox regulation (Figure 4A, pink), and cytoskeletal
dynamics (Figure 4A, orange) in the UUO kidney. In contrast,
in the TG2 interactome of the normal kidney (Figure 4B),
there were changes in the topology of interconnections among
the same functionally related protein groups, which were less
represented, but denser clusters of metabolic proteins were
evident (Figure 4B). Therefore, TG2 clearly becomes more
interactive with vesicular trafﬁcking proteins in the UUO as
well as proteins linked to actin dynamics and ECM events.
Matching of the TG2 Interactome with the UUO
Proteome
To exclude any concentration-dependent association with
TG2, we evaluated if the proteins of the TG2UUO interactome
were also over-represented in theUUOproteome or associated
with TG2 without being upregulated in the UUO. To this aim,
we proﬁled the UUO and sham-operated kidney proteomes by
Table 1. Continued
Identiﬁcation Name n P Value U/S
ARC1B Actin-related protein 2/3 complex subunit 1B 5 4.28E202 U
SCFD1 Sec1 family domain-containing protein 1 5 4.30E202 U/S
COPB2 Coatomer subunit-b 5 4.42E202 U
FA49B Protein FAM49B 5 4.62E202 U
MYH14 Myosin-14 5 4.79E202 U
SNX1 Sorting nexin-1 4 4.81E202 U
PLST Plastin-3 5 4.82E202 U
GBP2 IFN-induced guanylate binding protein 2 5 5.00E202 U
SYEP Bifunctional glutamate/proline–tRNA ligase 5 5.17E202 U
TCPA T-complex protein 1 5 5.25E202 U
CLIC1 Chloride intracellular channel protein 1 5 5.33E202 U
The association was evaluated by z analysis58 (P#0.05; n$4) of n=5 independent experiments, which combined TG2 IP and SWATHMS, using the TG2-null mice as
background control (as outlined in Figure 2, A and D). Nuclear and mitochondrial membrane proteins (Supplemental Figure 1) as well as ribosomal proteins
(Supplemental Table 1) weremanually removed. Proteins are denoted by full name and UniProtKB protein entry name (identiﬁcation), and they are listed according
to the speciﬁcity of the interaction with TG2 (P value). U/S, TG2-associated proteins in UUO and sham control membranes; U, TG2-associated proteins uniquely
found in UUO membranes.
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Table 2. Speciﬁc TG2 partner proteins in the sham control kidney (membrane fraction)
Identiﬁcation Name n P Value U/S
PRS4 26S protease regulatory subunit 4 5 5.22E209 S
PSME1 Proteasome activator complex subunit 1 5 8.91E207 S
NEDD4 E3 ubiquitin-protein ligase NEDD4 5 3.03E205 S
K2C1B Keratin, type II cytoskeletal 1b 4 8.40E205 S
UN45A Protein unc-45 homolog A 5 1.04E204 S
TGM2 Transglutaminase 2 5 1.21E204 U/S
PRUNE Protein prune homolog 5 1.31E204 S
NIBL1 Niban-like protein 1 5 1.41E204 S
PLEC Plectin 5 1.80E204 S
IF4G3 Eukaryotic translation initiation factor 4-g3 5 1.82E204 U/S
SERA D-3–phosphoglycerate dehydrogenase 5 1.85E204 U/S
TERA Transitional endoplasmic reticulum ATPase 5 2.49E204 U/S
PH4H Phenylalanine-4-hydroxylase 5 2.67E204 S
TOM1 Target of Myb protein 1 4 3.37E204 S
PTN6 Tyrosine-protein phosphatase nonreceptor type 6 4 4.04E204 U/S
ACY3 N-acyl-aromatic-L-amino acid amidohydrolase 4 5.54E204 S
TCPZ T-complex protein 1 5 6.52E204 U/S
DEST Destrin 5 8.51E204 S
UB2D3 Ubiquitin-conjugating enzyme E2 D3 5 9.25E204 S
KAD1 Adenylate kinase isoenzyme 1 5 9.92E204 S
G3P Glyceraldehyde-3-phosphate dehydrogenase 5 1.05E203 S
USP93 Probable ubiquitin C-terminal hydrolase FAF-X 5 1.27E203 S
PDIA1 Protein disulﬁde-isomerase 4 1.40E203 S
CASP3 Caspase-3 4 1.42E203 S
UBP24 Ubiquitin C-terminal hydrolase 24 4 1.43E203 S
MEP1A Meprin A subunit-a 5 1.68E203 S
ARF6 ADP-ribosylation factor 6 5 1.88E203 S
SPTA1 Spectrin a-chain, erythrocytic 1 5 1.97E203 U/S
TM55B Type 1 phosphatidylinositol 4,5-bisphosphate 4-phosphatase 4 3.22E203 S
KCRB Creatine kinase B type 5 4.11E203 S
RHEB GTP binding protein Rheb 5 4.12E203 S
SCFD1 Sec1 family domain-containing protein 1 5 4.24E203 U/S
ST1A1 Sulfotransferase 1A1 5 4.51E203 S
ANXA2 Annexin A2 5 5.38E203 S
CALM Calmodulin 5 5.39E203 U/S
F120A Constitutive coactivator of PPARg-like protein 1 5 5.77E203 U/S
OLFM4 Olfactomedin-4 5 5.80E203 S
IST1 IST1 homolog 5 6.01E203 S
PRDX2 Peroxiredoxin-2 4 6.07E203 U/S
PP1A Serine/threonine-protein phosphatase PP1-a catalytic subunit 4 6.08E203 S
NLTP Nonspeciﬁc lipid transfer protein 5 6.29E203 S
PPBT Alkaline phosphatase, tissue-nonspeciﬁc isozyme 5 6.39E203 S
PDC6I Programmed cell death 6–interacting protein 5 6.41E203 U/S
ENOA a-Enolase 4 6.90E203 S
FBLN1 Fibulin-1 5 7.33E203 S
LIMS1 LIM and senescent cell antigen-like–containing domain protein 1 5 7.55E203 U/S
TCPG T-complex protein 1 subunit-g 5 7.61E203 S
GGA1 ADP-ribosylation factor binding protein GGA1 5 8.30E203 S
IRF3 IFN regulatory factor 3 4 8.39E203 S
TBB5 Tubulin b5-chain 5 8.92E203 S
FARP1 FERM, RhoGEF, and pleckstrin domain-containing protein 1 5 9.63E203 S
DJB11 DnaJ homolog subfamily B member 11 4 1.03E202 S
ARF5 ADP-ribosylation factor 5 5 1.03E202 S
ARPC5 Actin-related protein 2/3 complex subunit 5 4 1.06E202 S
ARHGC Rho guanine nucleotide exchange factor 12 5 1.10E202 S
ARL2 ADP-ribosylation factor–like protein 2 5 1.14E202 S
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Table 2. Continued
Identiﬁcation Name n P Value U/S
AT1B1 Sodium/potassium-transporting ATPase subunit-b1 5 1.21E202 S
MGST3 Microsomal glutathione S-transferase 3 5 1.21E202 S
NSF Vesicle-fusing ATPase 5 1.28E202 S
PGK1 Phosphoglycerate kinase 1 4 1.38E202 U/S
ARL1 ADP-ribosylation factor–like protein 1 5 1.42E202 S
AT1A1 Sodium/potassium-transporting ATPase subunit-a1 5 1.43E202 S
CUL5 Cullin-5 5 1.43E202 S
VILI Villin-1 5 1.51E202 S
S12A3 Solute carrier family 12 member 3 5 1.55E202 S
KS6A3 Ribosomal protein S6 kinase-a3 5 1.58E202 S
TBA4A Tubulin a4A-chain 5 1.62E202 S
VATA V-type proton ATPase catalytic subunit A 5 1.70E202 S
SYWC Tryptophan–tRNA ligase 5 1.75E202 S
CAH9 Carbonic anhydrase 9 4 1.76E202 S
RAC2 Ras-related C3 botulinum toxin substrate 2 5 1.85E202 S
HBA Hemoglobin subunit-a 5 1.88E202 S
RAB10 Ras-related protein Rab-10 5 1.98E202 S
PCKGC Phosphoenolpyruvate carboxykinase 5 2.08E202 U/S
NRK1 Nicotinamide riboside kinase 1 5 2.11E202 S
VPS35 Vacuolar protein sorting–associated protein 35 5 2.25E202 S
SNX3 Sorting nexin-3 5 2.27E202 S
ACSA Acetyl-CoA synthetase 5 2.29E202 S
DNJA2 DnaJ homolog subfamily A member 2 5 2.29E202 S
ST1D1 Sulfotransferase 1 family member D1 5 2.40E202 S
ANFY1 Rabankyrin-5 5 2.42E202 S
GLCTK Glycerate kinase 5 2.42E202 S
ARC1A Actin-related protein 2/3 complex subunit 1A 5 2.42E202 S
PDIA6 Protein disulﬁde-isomerase A6 5 2.53E202 S
VATB2 V-type proton ATPase subunit B 5 2.59E202 S
GCYA3 Guanylate cyclase–soluble subunit-a3 5 2.67E202 S
LYPA2 Acyl-protein thioesterase 2 5 2.68E202 S
RUFY3 Protein RUFY3 4 2.72E202 S
PICAL Phosphatidylinositol binding clathrin assembly protein 4 2.73E202 U/S
TBC9B TBC1 domain family member 9B 5 2.78E202 S
IQGA1 Ras GTPase-activating–like protein IQGAP1 5 2.99E202 U/S
RCN1 Reticulocalbin-1 4 3.03E202 S
ARP3 Actin-related protein 3 5 3.04E202 S
PGS1 Biglycan 5 3.18E202 U/S
NAMPT Nicotinamide phosphoribosyltransferase 5 3.20E202 U/S
ECHP Peroxisomal bifunctional enzyme 5 3.21E202 U/S
HS90B Heat shock protein HSP 90b 5 3.38E202 S
ITM2B Integral membrane protein 2B 5 3.60E202 S
MP2K2 Dual speciﬁcity mitogen-activated protein kinase kinase 2 5 3.62E202 S
DHRS4 Dehydrogenase/reductase SDR family member 4 4 3.62E202 S
TBA1A Tubulin a1A-chain 5 3.66E202 S
IF4A1 Eukaryotic initiation factor 4A-I 5 3.68E202 S
OXSR1 Serine/threonine-protein kinase OSR1 5 3.69E202 S
F213A Redox-regulatory protein FAM213A 5 3.76E202 U/S
CLIC4 Chloride intracellular channel protein 4 5 3.82E202 S
VDAC1 Voltage-dependent anion-selective channel protein 1 5 3.87E202 S
CAN2 Calpain-2 catalytic subunit 5 3.95E202 S
NDRG3 Protein NDRG3 5 4.06E202 S
CLH1 Clathrin heavy-chain 1 5 4.11E202 S
LAMB2 Laminin subunit-b2 4 4.21E202 U/S
FINC Fibronectin 5 4.27E202 U/S
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SWATH MS (Supplemental Tables 2 and 3). This was neces-
sary, because current UUO proteomes are of limited cover-
age.22 Of the 2106 proteins quantiﬁed in the UUO proteome,
195 were signiﬁcantly upregulated in kidneys post-UUO (Sup-
plemental Table 2), and 458 were downregulated
(Supplemental Table 3) (conﬁdence .80%). Original pro-
cessed data are provided as Supplemental Appendix 2.
TG2 signal was increased but only less than twice the phys-
iologic level (1.71-fold) (Supplemental Table 2, TGM2), con-
sistent with prior observations that UUO leads to an increase
Table 2. Continued
Identiﬁcation Name n P Value U/S
TS101 Tumor susceptibility gene 101 protein 4 4.31E202 S
DPYL3 Dihydropyrimidinase-related protein 3 5 4.39E202 S
ISG15 Ubiquitin-like protein ISG15 5 4.53E202 S
DRG2 Developmentally regulated GTP binding protein 2 5 4.71E202 S
RN213 E3 ubiquitin-protein ligase RNF213 4 4.73E202 S
BAX Apoptosis regulator BAX 5 4.73E202 S
ADH1 Alcohol dehydrogenase 1 5 4.74E202 U/S
SPTN1 Spectrin a-chain, nonerythrocytic 1 5 5.25E202 U/S
EF1A1 Elongation factor 1-a1 5 5.34E202 S
The association was evaluated as described in Table 1. U/S, TG2-asociated proteins in UUO and sham-operated membranes; S, TG2-associated proteins uniquely
found in sham-operated membranes.
Figure 3. Functional distribution of TG2-associated proteins in kidney membranes reveals a difference in TG2 partners between the
UUO and normal (sham) status. TG2-associated proteins were clustered depending on their functions in M. musculus investigated by
protein identiﬁcation search on UniProtKB database. (A) Pie charts display the distribution of the different functions of the TG2-associated
proteins in UUO or sham controls, with numbers next to each function name denoting how many proteins fall in the various functional
categories. (B) Column charts list proteins in the order of signiﬁcance of their association with TG2 (log10 P value) and are grouped
according to their function in UUO and sham controls (histogram bars). Dots under protein names denote proteins described in Results.
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in TG2 secretion rather than expression.12 Protein class anno-
tation terms were associated with ECMcomponents, cytoskel-
etal organization, and cell adhesion, forming signiﬁcant
clusters of the UUO proteome (P#0.05) (Figure 5A, Supple-
mental Table 4A).
Among the proteins most signiﬁcantly associated with TG2
in the UUO kidney (P#0.001 in Table 1), which were also
intensiﬁed in the UUO proteome (Figure 5C, right panel),
there were periostin (a marker of progres-
sive kidney injury in animal models of
CKD),23 myosin-1D, PROF1, CAZA-2,
heat shock proteinb1, FN, laminin, collagen
(COCA1), and actin nucleation complex
ARC1B. A number of these TG2 partners
sat in pathways over-represented in the
UUO model (“ECM-receptor interaction”
and “regulation of the actin cytoskeleton”)
(Supplemental Figure 2), suggesting that
they act in synergy with TG2 in ﬁbrosis pro-
gression. However, a signiﬁcant level of TG2
partners, such as HSP7C, SDC4, and the
antioxidant proteins glutathione peroxi-
dase-1 and GLRX1 (Figure 5C, left panel),
was either decreased or was not signiﬁcantly
over-represented in the UUO proteome,
raising the possibility that they could be es-
sential partners of TG2, some of whichwere
potentially implicated in the externalization
pathway of TG2 post-UUO.
TG2 Association with Exosomal
Proteins Post-UUO
The TG2 interactome has revealed that TG2
primarily interacts with a number of proteins
associated with vesicular trafﬁcking and EVs,
especially in the UUO condition. When the
TG2 partners identiﬁed in the UUO model
(Table 1)werematchedwithproteins collected
in the EVs (exosome) database ExoCarta (and
its compendium Vesiclepedia), almost all pro-
teins associated with TG2, either directly or
indirectly, were nominated in the database
(Table 3). These included the prominent exo-
some marker Alix (PDC6I), HSP7C, PROF1,
FLOT2, and heat shock protein HSP90-a, all
among the top 50 proteins reported in exo-
somes. Other signiﬁcant exosomal TG2 part-
ners less recurrent in the exosome database
were PRDX2, RAB1A, and SDC4 (Table 3).
These ﬁndings support the hypothesis that
TG2 may be trafﬁcked and externalized via
EVs, either of endosomal origin (exosomes)
or shed from the PM (ectosomes).
TG2 Secretion via Exosomes and
Ectosomes in Established Epithelial Cell Lines
Previous reports have shown that TG2 is mainly secreted by
TECs, although renal ﬁbroblasts and mesangial cells are less
investigated sources.4,5 To test the hypotheses that TG2 is ex-
ternalized in the UUO in EVs and that this pathway is in-
creased in the pathologic state, we used an established rat renal
TEC line (NRK52E) stably transfected with EGFP-tagged TG2
to facilitate tracking of TG2. Exosomes and ectosomes were
Figure 4. The interactome of TG2 in UUO and sham control kidney reveals increased
interactivity of TG2 with proteins related to vesicular trafﬁcking, cytoskeleton, and
ECM dynamics in the UUO model. The protein interaction network built from TG2-
associated proteins in (A) UUO and (B) sham-operated kidney membranes was
mapped against theM. musculus reference database using String V10.0 (http://string-
db.org). Candidates were selected using both known and predicted protein interac-
tions and a threshold conﬁdence level of 0.4 (default). Networks were imported in
Cytoscape and color coded according to the main functional nodes. The thickness of
the lines is proportional to the conﬁdence of the interactions.
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isolated from the supernatant of cells ac-
cording to standard protocols24,25 (Figure
6A). After removal of cells and cellular de-
bris, ectosomes were recovered by differen-
tial centrifugation in the P3 fraction
(2.973107 particles per 1 ml medium)
and smaller exosomes were recovered in the
P4 fraction (5.893107 particles per 1 mlme-
dium) as revealed by tunable resistive pulse
sensing analysis with a qNano instrument
(Figure 6B). The EV-free medium was col-
lected (S4), and all nonvesicular proteins
were recovered by TCA precipitation. The
fractions were subjected to Western blot
analysis using antibodies toward the EV
marker FLOT2 (Figure 6C).
To test for the presence of TG2 in theEVs
fractions, equal amounts of proteins (20mg)
extracted from ectosomes (P3) and exo-
somes (P4) and those from the vesicles-free
medium (S4; after TCA protein precipita-
tion) were immunoprobed using anti-
bodies against TG2 and the EGFP tag.
Both endogenous (75 kD) and EGFP-tagged
TG2 (100 kD) were clearly present in the
exosomes (P4) and in lower amounts in the
ectosome (P3) fraction (Figure 7A). Den-
sitometric analysis of TG2 relative to
FLOT2 revealed a trend of enrichment of
TG2 in the exosome fraction (P4) (Figure
7A). Cells were also stimulated by re-
combinant TGF-b1 (10 ng/ml) to simulate
conditions of ﬁbrogenesis in vitro. TGF-b1
did not change the level of TG2 in the total
cell lysate (TL) but caused a trend of in-
crease in the exosome-associated TG2
(Figure 7B). The cytokine affected the ex-
pression of FLOT2 in TL and EVs but with-
out reaching signiﬁcance (Figure 7B).
When the same experiment was conducted
in the nontransfected NRK52E cells, TG2
was present prevalently in exosomes (Fig-
ure 7C). Treatment with TGF-b1 caused a
trend of increase in TG2 in the exosomal
fraction, which became enriched in TG2
relative to FLOT2 expression. As an addi-
tional analysis, we isolated exosomes and
ectosomes from an established renal ﬁbro-
blast cell line (NRK49F). TG2 was present
in the ectosomal and exosomal fractions,
and the band was increased by TGF-b1
(Supplemental Figure 3). The EV-free me-
dium (S4) was also collected from both the
EGFP-TG2 NRK52E clone and the WT
NRK52E, and all proteins were recovered
Figure 5. Interrogation of the UUO proteome with TG2-interacting proteins
uncovers essential partners of TG2 in UUO kidney membranes. The proteomes
of the UUO kidneys and sham-operated control kidneys were resolved by
quantitative SWATH acquisition proteomics. (A and B) Functional distribution of
proteins with signal (A) increased (n=195) or (B) decreased (n=458) on UUO
compared with sham control (conﬁdence $80%) was performed in PANTHER
using the relative annotation terms ontologies. Each pie chart sector represents
the percentage of the proteome belonging to the speciﬁc PANTHER class over
the total number of class hits. (C) Interrogation of the UUO proteome (conﬁ-
dence $50%) with the TG2-interacting proteins identiﬁed in UUO kidney
membranes (P#0.05) and reported in Table 1. The 122 proteins speciﬁcally
associated with TG2 in UUO kidney membranes were plotted on the ordinate
axis according to the signiﬁcance (P value) of TG2 association and the abscissa
according to their expression in the UUO kidney proteome compared with sham
control proteome: log2(UUO/sham). A positive value on the abscissa indicates
the increased signal of a given TG2-associated protein partner on UUO com-
pared with the sham-operated condition (UUO/sham .1), and a negative value
indicates its decreased signal on UUO (UUO/sham ,1).
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Table 3. Matching of TG2 partner proteins to exosomal proteins
Identiﬁcation TG2-Associated Candidate Names in UUO
Found in Exosomes
Homo sapiens Rattus norvegicus
DESP Desmoplakin Match
HSP7Ca Heat shock cognate 71-kD protein Match Match
CALM Calmodulin Match Match
CAZA2 F-actin–capping protein subunit-a2 Match Match
GPX1 Glutathione peroxidase 1 Match Match
ADH1 Alcohol dehydrogenase 1 Match Match
POSTN Periostin Match Match
MYO1D Unconventional myosin-Id Match
GLRX1 Glutaredoxin-1 Match
GLRX3 Glutaredoxin-3 Match Match
PROF1a Proﬁlin-1 Match Match
TGM2 Transglutaminase 2 Match Match
HSPB1 Heat shock protein-b1 Match Match
VATH V-type proton ATPase subunit H Match Match
ADDG g-Adducin
AT2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Match Match
SVIL Supervillin
COR1C Coronin-1C Match Match
IQGA1 Ras GTPase-activating–like protein IQGAP1 Match Match
TCPE T-complex protein 1
UBP5 Ubiquitin C-terminal hydrolase 5
FLOT2a Flotillin-2 Match Match
NAMPT Nicotinamide phosphoribosyltransferase Match Match
PCKGC Phosphoenolpyruvate carboxykinase Match Match
RAB1A Ras-related protein Rab-1A Match Match
SDC4 Syndecan-4 Match Match
LDHAa L-lactate dehydrogenase A-chain Match Match
MYO1G Unconventional myosin-Ig Match
K1C20 Keratin, type I cytoskeletal 20 Match
COEA1 Collagen-a1(XIV) chain Match
COCA1 Collagen-a1(XII) chain Match
HIP1 Huntingtin-interacting protein 1 Match
LIMS1 LIM and senescent cell antigen-like–containing domain protein 1 Match Match
SAR1B GTP binding protein SAR1b Match
SPTA1 Spectrin a-chain, erythrocytic 1
FLNA Filamin-A Match Match
ANK3 Ankyrin-3 Match
PSD11 26S proteasome non-ATPase regulatory subunit 11 Match
PGBM Basement membrane–speciﬁc heparan sulfate proteoglycan core protein (Perlecan)
LSP1 Lymphocyte-speciﬁc protein 1 Match
GELS Gelsolin Match Match
YKT6 Synaptobrevin homolog YKT6 Match
PTN6 Tyrosine-protein phosphatase nonreceptor type 6 Match
FLNB Filamin-B Match Match
TLN2 Talin-2 Match Match
PGK1a Phosphoglycerate kinase 1 Match Match
PICAL Phosphatidylinositol binding clathrin assembly protein Match Match
F120A Constitutive coactivator of PPARg-like protein 1 Match
PRDX2 Peroxiredoxin-2 Match Match
KCC2D Calcium/calmodulin-dependent protein kinase type II subunit-d Match
RTN4 Reticulon-4 Match Match
SERA D-3-phosphoglycerate dehydrogenase Match
KC1A Casein kinase I isoform-a Match
DCTN1 Dynactin subunit 1 Match Match
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Table 3. Continued
Identiﬁcation TG2-Associated Candidate Names in UUO
Found in Exosomes
Homo sapiens Rattus norvegicus
ADDA a-Adducin Match
PGS2 Decorin Match
IF4G3 Eukaryotic translation initiation factor 4-g3 Match
RHG18 Rho GTPase-activating protein 18 Match
CAPZB F-actin–capping protein subunit-b Match Match
MVP Major vault protein Match Match
TERAa Transitional endoplasmic reticulum ATPase Match
ACTBa Actin, cytoplasmic 1 Match Match
PGS1 Biglycan Match
K1C14 Keratin, type I cytoskeletal 14 Match
PLSL Plastin-2 Match Match
AP2A2 AP-2 complex subunit-a2 Match
FINC Fibronectin Match
CLCB Clathrin light-chain b Match
SNX4 Sorting nexin-4 Match
SPTB1 Spectrin b-chain, erythrocytic Match
ZO1 Tight junction protein ZO-1 Match
DREB Drebrin Match
CAN1 Calpain1 Match
PDLI5 PDZ and LIM domain protein 5 Match
PUR6 Multifunctional protein ADE2 Match Match
MY18A Unconventional myosin-XVIIIa Match
CLCA Clathrin light-chain A Match Match
IRGM1 Immunity-related GTPase family M protein 1
NEB2 Neurabin-2
K2C6B Keratin, type II cytoskeletal 6B Match
AP2A1 AP-2 complex subunit-a1 Match
LYPA1 Acyl-protein thioesterase 1 Match Match
PDC6Ia Programmed cell death 6–interacting protein Match Match
AP2B1 AP-2 complex subunit-b Match Match
K1C19 Keratin, type I cytoskeletal 19 Match
GRP78 78-kD Glucose-regulated protein Match Match
ARK72 Aﬂatoxin B1 aldehyde reductase member 2 Match Match
SNTB2 b2-Syntrophin Match
MYO1B Unconventional myosin-Ib Match
K6PP ATP-dependent 6-phosphofructokinase, platelet type
C1QB Complement C1q subcomponent subunit B Match Match
F213A Redox-regulatory protein FAM213A Match
HS90Aa Heat shock protein HSP 90a Match Match
GAK Cyclin-G–associated kinase Match
SPTN1 Spectrin a-chain, nonerythrocytic 1 Match
UCK1 Uridine-cytidine kinase 1
ECHP Peroxisomal bifunctional enzyme Match Match
ES8L2 EGF receptor kinase substrate 8–like protein 2 Match
MOESa Moesin Match Match
PNCB Nicotinate phosphoribosyltransferase Match Match
MYH10 Myosin-10 Match Match
RBGPR Rab3 GTPase-activating protein noncatalytic subunit Match
VIME Vimentin Match Match
SERPH Serpin 1H Match Match
RPN1 Dolichyl-diphosphooligosaccharide–protein glycosyltransferase subunit 1 Match
LAMB2 Laminin subunit-b2 Match Match
GSTT1 Glutathione S-transferase-u1 Match
TCPQ T-complex protein 1
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by TCA precipitation. A trace of endogenous TG2 was occa-
sionally present freely in the culture medium (S4) of NRK52E-
expressing EGFP-TG2 on TCA precipitation (Figure 7, A and
B), and TG2 immunoreactivity was seen in high molecular
weight polymers in the S4 fraction of WT NRK52E (Figure
7C). Our data suggest that the free TG2 may be transient and
unstable and that it either self-polymerizes or becomes incor-
porated in circulating proteins (Figure 7C, asterisk); moreover,
it is not increased by TGF-b1 (Figure 7, B and C).
To gain insights into the location of TG2 within EVs, we
devised an experiment aimed atmeasuring the catalytic activity
of TG2 of whole EVs and lysed EVs (providing the total EVs
homogenate) isolated fromNRK52E cells. As a control, we also
measured TG2 activity in lysed cell homogenates and whole
cells. In the ectosomes (P3), TG2 activity was similar in the
intact vesicles and vesicles lysed in a buffer dissolving cytosolic
proteins; in the exosomes (P4), there was a higher proportion
of TG2 detected in the intact particles compared with the EV
lysate, suggesting that TG2 is enriched on the surface of exo-
somes but without reaching signiﬁcance (P=0.14). No TG2
activity was detected in the EV-free medium, and levels of
TG2 were similar on the surface of NRK52E cells and in the
cell lysate (Figure 7D).
Collectively, these results show that TG2 is clearly present in
EVs and suggest that TGF-b1 directs TG2 toward exosome
secretion.
Inhibition of Neutral Sphingomyelinase Affects
Exosome Release of TG2
In several mammalian cell types, the biogenesis of exosome
secretion depends on sphingomyelinase for the production of
ceramide of which exosomes are rich.26 We, therefore, inves-
tigated whether the sphingomyelinase inhibitor GW4869,
which blocks neutral sphingomyelinase (N-SMase), affected
exosome release of TG2. After treatment of NRK52E-express-
ing EGFP-TG2 with GW4869 (10 mM) for 16 hours,27 FLOT2
was decreased in the exosomal fraction (P4) (Figure 8A), con-
sistent with a reduction of total exosome release, and this was
accompanied by a marked reduction of TG2 in the same frac-
tion (Figure 8A). The ectosome fraction (P3) did not seem to
be sensitive to inhibition of N-SMase as previously described
in glial cells,24 and GW4869 produced no difference in the
ectosome release of TG2 (Figure 8A). Vesicular export of TG2
was visualized by immunoﬂuorescence staining using high-res-
olution confocal microscopy in EGFP-TG2–expressing
NRK52E cells. Extracellular TG2 was detected by an anti-
EGFP antibody in nonpermeabilized cells (denoted by the
red ﬂuorescence), whereas the green ﬂuorescence represents
the total EGFP-TG2. Minimum washing of the monolayer be-
fore ﬁxation to prevent exosome loss revealed an intense punc-
tate pattern of extracellular EGFP-TG2 staining, which was
increased in TGF-b1–stimulated cells. GW4869 visibly inhibi-
ted extracellular EGFP-TG2 staining, suggesting that it inhibits
TG2 export (Figure 8B). EGFP ﬂuorescence visualization of
exosomes isolated from NRK52E-expressing EGFP-TG2 and
incubated with WT NRK52E revealed a similarly punctuated
staining, which was retained in the WT NRK52E monolayer
after several washes, suggesting that this consists of EVs con-
taining EGFP-TG2 (Figure 8C, 2Hep). Pretreatment of
NRK52E with heparitinase to remove the HS chains before
addition of EGFP-TG2–containing exosomes reduced the exo-
some uptake by 49% (P,0.01) (Figure 8C, +Hep), suggesting a
role for cell surface HS in the capturing of EVs.
To attenuate the formation of ectosomes, we used the in-
hibitor of Na+/H+ exchanges amiloride, which interferes with
the activity of the efﬂux pumps expressed on acidic vacuoles
and the exocytosis of micropinosomes.28–31 Ectosomes (P3)
formed in a greater proportion than exosomes (P4) in a short
Table 3. Continued
Identiﬁcation TG2-Associated Candidate Names in UUO
Found in Exosomes
Homo sapiens Rattus norvegicus
TCPZ T-complex protein 1 Match
IRAK4 IL-1 receptor–associated kinase 4
C1TC C-1-tetrahydrofolate synthase Match Match
ARC1B Actin-related protein 2/3 complex subunit 1B Match Match
SCFD1 Sec1 family domain–containing protein 1 Match
COPB2 Coatomer subunit-b Match Match
FA49B Protein FAM49B Match Match
MYH14 Myosin-14 Match
SNX1 Sorting nexin-1 Match
PLST Plastin-3 Match
GBP2 IFN-induced guanylate binding protein 2 Match
SYEP Bifunctional glutamate/proline–tRNA ligase Match Match
TCPAa T-complex protein 1 Match Match
CLIC1a Chloride intracellular channel prot 1 Match Match
Partners of TG2 in the UUO kidney (Table 1) listed in order of signiﬁcance of their association with TG2 were matched with exosomal proteins provided by the
Exocarta database59 (H. sapiens and R. norvegicus datasets).
aThese proteins are among the top 50 exosome markers.
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time of incubation (10 minutes) as previously shown,32 and
they were revealed by the faint FLOT2 staining in the exosome
fraction (Figure 8D). Amiloride incubation lowered FLOT2 in
the ectosomes (P3), being that amiloride is an inhibitor of MV
formation,33 and consistent with this, there was a reduction in
TG2 in ectosomes (Figure 8D).
Collectively, these results indicate that TG2 is transported
into exosomes and ectosomes and that this pathway is stimu-
lated by proﬁbrogenic TGF-b1 in exosomes.
Recruitment of TG2 in Exosomes Depends on SDC4
Another protein that we found speciﬁcally present in TG2
UUO interactome is the cell surface HS proteoglycan SDC4
(Table 1). Syndecans have been reported to bind cargowithHS
chains, leading to their clustering and recruitment of synte-
nin-1 and Alix for membrane budding with exosome forma-
tion.34 Therefore, we hypothesized that TG2 may be recruited
as an HS binding cargo and targeted to exosomes by SDC4. To
test the role of SDC4 in EV-associated TG2 secretion,
NRK52E-expressing EGFP-TG2 was transiently transfected
with either rat SDC4-targeting siRNA or scrambled control
siRNA. SDC4 reduction by SDC4-target-
ing siRNA (SDC4 KO) was conﬁrmed by
Western blotting of the TL (Figure 9A).
As a control for the proteoglycan immu-
nodetection (which is notoriously difﬁ-
cult), NRK52E transiently transfected
with a hemagglutinin (HA)-tagged SDC4
construct revealed a similar band in the 30-
kD range when probed with anti-HA anti-
body (Figure 9B). Culture medium was
collected from the SDC4 KO cells and EV
fractions separated by serial centrifuga-
tion. Proteins and complexes from EV-de-
prived medium were precipitated by TCA
as described before. As shown in Figure
9C, KO of SDC4 by siRNA did not change
TG2 expression in TL, but it greatly re-
duced TG2 in exosome (P4) fractions, af-
fecting the vesicular secretion of TG2.
SDC4 KO also reduced the low level of
free TG2 found in the EV-free conditioned
medium (S4) (Figure 9C). As shown by
quantiﬁcations (Figure 9D), KO of SDC4
by siRNA did not change expression of
FLOT in ectosome (P3) and exosome
(P4) fractions. IP of SDC4 from exosomes
and ectosome lysates revealed SDC4 im-
munoreactivity in the two fractions, but
SDC4 clearly pulled down TG2 only from
exosomes (Figure 9E), suggesting a direct
interaction of TG2 and SDC4 within EVs
only in exosomes. Given the afﬁnity of TG2
for the HS chains of SDC413,35 and their
coassociation within exosomes shown
here, our data suggest that TG2 is recruited as an HS binding
cargo and targeted to exosomes by SDC4.
Vesicular Trafﬁcking of TG2 Ex Vivo Depends on SDC4
ToexamineTG2release and investigate the roleplayedbySDC4
further, primary cortical TECs, ﬁbroblasts, andmesangial cells
were isolated from WT (SDC4+/+) and SDC4 KO (SDC42/2)
mice,36 and the level of extracellular TG2 was measured in live
cells by a well established enzymatic assay.37 SDC4 deletion
(SDC42/2) resulted in lower TG2 externalization in all of the
three primary renal cell types (Figure 10A), with no changes in
the total level of TG2 activity between SDC4+/+ and SDC42/2
genotypes (Figure 10B). TECs displayed the highest level of
extracellular TG2 comparedwith the total TG2 activity (Figure
10, A and B). The decreased TG2 externalization in SDC42/2
cells (Figure 10A) was accompanied by a lower level of mem-
brane TG2 as measured by Western blotting of membrane
fractions (Figure 10C) and an increased level of cytosolic
TG2 (Figure 10D), suggesting TG2 retention. Total TG2 ex-
pressionwas not lowered by SDC4 KOwhen revealed byWest-
ern blotting of TLs (Figure 10E). The increment in total TG2
Figure 6. A differential centrifugation approach allows the isolation of EVs subpop-
ulations from NRK52E conditioned medium. (A) Flowchart of the differential centri-
fugation steps for the isolation of EVs. P1–P4 indicate pellets, and S1–S4 indicate
supernatants. (B) Analysis of microparticle size distribution in fractions P3 and P4 was
performed by nanoparticle tracking analysis with qNano (Izon). Ectosomes were re-
covered from the P3 fraction, and exosomes were recovered from the P4 fraction.
Representative particle size distributions of an ectosome-enriched 10,000-g pellet
(dark gray) and an exosome-enriched 110,000-g pellet (light gray). (C) Expression of
FLOT2 was measured by Western blotting in equal amounts from the differential
centrifugation fractions obtained from the conditioned medium of NRK52E cells cul-
tured in serum-free conditions.
J Am Soc Nephrol 29: ccc–ccc, 2018 Mechanism of Transglutaminase-2 Release in CKD 15
www.jasn.org BASIC RESEARCH
protein in SDC42/2mesangial cells, compared with SDC4+/+
cells, may be a compensatory event of TG2 overproduction
consequent to the defect in TG2 secretion (Figure 10E). There-
fore, SDC4 KO impaired TG2 membrane distribution and
externalization, with an increased retention of intracellular
TG2 in the three primary renal cell types. To visualize TG2
trafﬁcking in live cells, the primary WTand SDC4-null TECs
were transiently transfected with an EGFP-
tagged TG2 cDNA and visualized by live
confocal microscopy (Supplemental Movie
1). EGFP-TG2 was recruited in globular el-
ements continuously protruding and re-
tracting from the PM and moving along
the PM at the periphery of the cell. Budding
of TG2-storing vesicles from the PM was
evident. However, EGFP-TG2 was less dy-
namic and appeared conﬁned in the cytosol
in the SDC4-null TECs, which also had less
budding activity than the WT TECs. When
SDC4 cDNAwas transfected back to SDC4-
null TECs, EGFP-TG2 vesicular blebbing
was largely resumed, and budding was re-
constituted toWT levels (quantiﬁcations of
extracellular TG2 activity are in Figure 10F,
Supplemental Movie 1). These data show
for the ﬁrst time a dependence of TG2 ve-
sicular trafﬁcking on SDC4 and also suggest
that SDC4 could be implicated in general
EV dynamics of TECs involving cargo pro-
teins with afﬁnity for HS, like TG2.
TG2 Positive Exosomes in Urine
Samples of Patients with CKD
To verify whether TG2 is released via exo-
somes in human CKD, we isolated EVs from
pooled urine samples collected from a small
cohort of patients with CKD (n=10) with
stages 3 and 4 primary kidney disease and
from healthy controls (n=5). Immunoblot-
ting of equal amounts of samples (Supple-
mental Figure 4) revealed the presence of
TG2 exclusively in the exosomes (P4) frac-
tions, with an intensiﬁcation of the band in
the exosomes from the patients with CKD.
There was no TG2 band in the ectosomes
(P3) or the EV-free urine. FLOT was used
as an EV marker, and it also intensiﬁed in
the exosomes of patients with CKD.We pre-
viously reported the increased presence of
TG2 in urines of patients with CKDby sand-
wich ELISA.38 Data in this study show that
TG2 is conveyed by EVs in urines, validating
our ﬁnding in human CKD.
DISCUSSION
This is the ﬁrst unbiased global analysis of TG2-interacting
proteins in a model of CKD (the murine UUO type). TG2-
associated proteins were identiﬁed using an original targeted
proteomic strategy by combining TG2 IP from whole-kidney
membrane preparations of WT kidneys with negative control
Figure 7. TG2 is present in vesicles of endosomal and plasma membrane origin in
established TEC lines. (A and B) NRK52E-expressing EGFP-TG2 and (C) WT NRK52E
cells were grown in serum-free medium for 36 hours (A) without and (B and C) with
supplementation of 10 ng/ml TGF-b1. After incubation, culture medium was col-
lected, and vesicular fractions (P3 and P4) were separated by serial centrifugation as
shown in Figure 6. Proteins from vesicles-deprived medium were concentrated by
TCA precipitation (S4). Fractions and cell lysate (TL) were immunoprobed with primary
antibodies toward the EGFP tag, TG2, or FLOT2. Intensity of immunoreactive bands
was quantiﬁed by densitometric analysis and normalized to FLOT2 expression. Data
represent mean values of three independent experiments 6SEM. Black arrowhead,
endogenous TG2; white arrowheads, EGFP-TG2. *TG2 polymers. (D) EVs obtained
from NRK52E EGFP-TG2 conditioned medium were either lysed in a mild lysis buffer
to obtain a total lysate or resuspended as intact vesicles in sample buffer (from a tissue
transglutaminase picoassay kit). The transamidating activity of TG2 was measured in
either the whole EVs or the EV lysate by a sensitive “picoassay.” As a control, TG2
activity was also measured in TL and whole cells. Data represent mean values of three
independent experiments 6SEM.
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IP from TG2-null kidneys from inbred mice. Furthermore,
TG2 complexes have been used to interrogate the UUO pro-
teome. Proteomes were resolved by SWATHdata-independent
acquisition MS.18 The proposed strategy could be adapted for
precision-targeted proteomics in other systems.
Bioinformatic analysis of the TG2-associated proteins in
the UUOmodel revealed enrichment of proteins involved in
vesicular transport, and among them, a striking number
were exosome-associated proteins. Because the TG2 part-
ners involved in vesicular trafﬁcking were not increased in
theUUOproteome comparedwith the healthy proteome, we
deduce that their function in TG2 trafﬁcking is caused by
their augmented interaction with TG2 on UUO, excluding
the possibility of a concentration-dependent association.
However, almost all proteins regulating ECM receptor or-
ganization and actin dynamics that we found signiﬁcantly
upregulated in the UUO proteome were also TG2-interact-
ing proteins in the UUO. Collectively, these ﬁndings suggest
the existence of a pathway of TG2 secretion during ﬁbrosis
progression driven by vesicular trafﬁcking followed by the
interaction of secreted TG2 with a protein network respon-
sible for ECM dynamics, leading to ﬁbrotic remodeling and
expansion. The diminished scarring index and lower level of
active TGF-b in the TG2 KO kidneys that we have reported
here align well with the molecular connections that link
TG2 to the ﬁbrotic kidney proteome generated by this study,
conﬁrming the role of TG2 in the extracellular milieu in
ﬁbrosis progression.
By exploiting the MS data in vitro and ex vivo, we have
uncovered a novel pathway for the cellular export of TG2 in
TECs. We have shown that TG2 is predominantly secreted in
association with exosomes and that TG2-bearing exosomes
require the sphingolipid ceramide for their production. Fur-
thermore, TG2 enrichment in exosomes is stimulated by TGF-
b1, although on the basis of quantiﬁcations of exosomes via
FLOT, a well characterized EV marker and partner of TG2 in
vivo post-UUO, we cannot rule out a general increase in EV
production by TGF-b1. Exosomes form from endosomes by
budding into late endosomes (multivesicular bodies), which
then fuse with the PM, releasing intraluminal vesicles or exo-
somes.39 The endosomal sorting complex required for trans-
port (ESCRT) machinery is the main system controlling the
sorting of proteins into exosomes.39 Loading of syndecan HS
proteoglycans (SDC1 and SDC4) with intracellular cargos able
to bind the proteoglycan HS chains leads to syndecan cluster-
ing and recruitment of cytosolic adaptor protein syntenin-1,
which by direct interaction with Alix, adapts syndecan and
syndecan-bound cargoes to the ESCRTat the level multivesic-
ular body formation.34 In recent work, even TG2 itself has
been implicated in cargo recruitment to vesicles and is present
in exosomes in situations of abnormal proteostasis in an MEF
model.40
TG2 is an HS binding protein, and HS affects TG2 trafﬁck-
ing as shown in previous work12,13,35,41; consistent with this
observation, SDC4 emerged as a speciﬁc partner of TG2 in the
UUO kidney in this unbiased analysis. We and others have
previously identiﬁed SDC4 as a proﬁbrotic partner of
TG28,12,13 inﬂuencing its secretion but without a clear mech-
anism. Here, we have for the ﬁrst time unraveled that the in-
teraction of TG2 with HS SDC4 may play a fundamental role
in the targeting of TG2 to exosomes. SDC4 and TG2 were
coimmunoprecipitated from exosomal lysates, and SDC4
was required for exosomal secretion of TG2, this being greatly
diminished by siRNA targeted to SDC4. Ex vivo, live imaging
of primary cortical TECs from SDC4 KO kidney showed re-
duced vesicular trafﬁcking of TG2 to the cell surface, which
was compensated by SDC4 add back. TG2 was retained in the
cytosolic fraction not only of SDC4 KO TECs but also, of
primary ﬁbroblasts and mesangial cells isolated from SDC4
KO kidneys, suggesting that SDC4 regulates TG2 distribution
in all of the main renal cell types. In vivo, SDC4 was a TG2-
interacting partner only in the diseased kidney, consistent with
Figure 8. EV release of TG2 is reduced by inhibition of exosome and ectosome synthesis. (A) Exponentially growing NRK52E-
expressing EGFP-TG2 cells were cultured in serum-free medium supplemented with GW4869 (10 mM; +) or DMSO (vector; 2) for
16 hours. TL, ectosome (P3), and exosome (P4) fractions were blotted with anti-GFP (EGFP) and anti-FLOT2 antibodies. Band intensities
per area measured by densitometric analysis are shown underneath the blots. (B) NRK52E EGFP-TG2 cells were grown in an eight-well
chamber with and without 10 ng/ml TGF-b1 and treated with GW4869 as described in A. Extracellular EGFP-TG2 was detected in cells
ﬁxed by paraformaldehyde (3% [wt/vol]) but not permeabilized using a rabbit polyclonal anti-GFP antibody followed by a goat anti-
rabbit Alexa Fluor 568 antibody (red). Nuclei were stained with 49,6-diamidino-2-phenylindole (blue). The green ﬂuorescence denotes
total EGFP-TG2. Representative confocal microscopy sections (10 mm) are presented, and they were acquired by a Leica TCS confocal
microscope. White arrows identify the cell perimeter. Extracellular EGFP-TG2 was quantiﬁed by ImageJ intensity analysis on at least
eight nonoverlapping images per treatment and is presented as mean relative intensity of red (extracellular EGFP-TG2) over green
(total EGFP-TG2) 6SEM expressed relative to the control cells without GW4869 (equalized to one). *P,0.05; **P,0.01; ***P,0.01. (C)
Exosomes from NRK52E EGFP-TG2 cells were isolated and incubated on a monolayer of WT NRK52E cells for 3 hours. Cells were
washed three times in PBS and ﬁxed in paraformaldehyde, but they were not permeabilized. EGFP ﬂuorescence (green) was clearly
visible in particles with estimated diameter of ,0.5 mm. Nuclei were stained with 49,6-diamidino-2-phenylindole. Pretreatment of the
NRK52E cell monolayer with heparitinase (+Hep) to digest cells surface HS chains led to a decrease in the uptaken EGFP-TG2–bearing
exosomes. (D) NRK52E-expressing EGFP-TG2 cells were exposed to 1 mM amiloride for 10 minutes in serum-free medium. TL, ec-
tosome (P3), and exosome (P4) fractions were blotted with anti-GFP and anti-FLOT2 antibodies. Band intensities per area were
measured as described in A.
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the notion that TG2 is secreted during ﬁbrosis progression
and only found in low amounts extracellularly in the normal
kidney.4,20 Therefore, our data suggest that TG2 would be
recruited as an HS binding cargo and targeted to exosomes
originating from late endosomes by SDC4. After secreted in
the extracellular environment, TG2 meets the high calcium
and low trinucleotide phosphates concentrations, which favor
the opening of TG2 and the acquisition of a linear conforma-
tion on substrate binding,42 that we and others have shown to
determine loss of heparin binding.35,41 Consistent with this
idea is the ﬁnding of a small portion of free soluble TG2 in our
cell experiments and the possibility that TG2 and/or EV-
bound TG2 may be transferred to HS of other receptor mol-
ecules in response to local changes in calcium levels in an
autocrine or paracrine fashion (Figure 11). For instance, per-
lecan is an ECMHS proteoglycan exclusively found in the TG2
UUO interactome, which could further recruit and distribute
TG2 in the matrix via the long HS chains. Furthermore, we
have shown that exosomal TG2 could be transferred horizon-
tally from the extracellular environment to TECs and that HS
chains of proteoglycans are required for the trafﬁcking of
TG2-rich exosomes. TG2 was also detected in ectosomes,
larger vesicles that bud directly from the PM, although in
much lower proportion than in exosomes. There was no clear
coprecipitation of SDC4 and TG2 from ectosome lysates (only
from exosome lysates), implying that SDC4 has no role or an
indirect role in recruiting TG2 to ectosomes.
The role played by EVs in disease is of growing importance,
although the ﬁeld is novel. Exosomes function in intercellular
and interorgan communication by transferring proteins,
mRNAs, and microRNAs to recipient cells.43 In seminal
work, it was shown that hypoxic tubular cells but not nor-
moxic counterparts secreted EVs that induced the expression
of TGF-b1, a-SMA, and F-actin in ﬁbroblasts, inducing their
subsequent activation.44 Therefore, it is clear that EVs coop-
erate in spreading and amplifying cell differentiation, leading
to sustained ﬁbrosis.43,44 Transfer of exosomal cargo to
neighboring cells allows tuning of cell behavior and rapid
phenotypic adjustment, including activation of ﬁbroblasts
into myoﬁbroblasts.44 Given the location of TG2 outside exo-
somes and speciﬁc interaction of TG2 with cell surface SDC4,
it is plausible that, after released, TG2 could assist in the cell-
cell trafﬁcking of exosomes, therefore inﬂuencing the transfer of
pathologic molecules conducive of ﬁbrosis. Furthermore, the
topology of TG2 on the outside of EVs would suggest that it
may also serve an adhesive function, which is an additional
important factor in the chronic healing process underlying
ﬁbrosis development. This suggestion is in line with the adhe-
sive role played by TG245 and recent evidence that exosomes
inﬂuence cell migration by serving as adhesive sites in the ma-
trix.46
TG2 is associated with wound healing and organ ﬁbrosis,
but what makes it an attractive target is that the enzyme is only
activated in disease on externalization. Therefore, inhibition of
TG2 is anticipated not to have an adverse effect in normal cells.
Wehave begun our investigation from an in vivomodel of CKD
providing a global analysis of the TG2 interactome present at
the interface between cells and the ECM niche–surrounding
cells and compared this with the CKD model proteome in an
unbiased manner. Our approach, which does not rely on
chemical crosslinking, has not detected integrin16 or puriner-
gic receptor17 as TG2 secretion partners in ﬁbrotic kidney or
attributed TG2 release to PM vesicular shedding as is observed
in cancer,47 but it has identiﬁed exosome secretion as a key
novel mechanism for the cell surface trafﬁcking of ﬁbrogenic
TG2 in an SDC4-dependent manner. The presence of TG2 in
urinary exosomes from a pool of patients with CKD has con-
ﬁrmed the importance of the ﬁnding in human pathology.
Our study changes the way that TG2 cell surface trafﬁcking
is seen and suggests that therapeutic block of vesicular TG2
could potentially impede TG2-driven matrix accumulation
and exosome-mediated transfer of TG2 from cell to cell during
ﬁbrosis progression.
CONCISE METHODS
Experimental details are provided in Supplemental Material.
Experimental Models
Experimental UUO48 was performed on fully backcrossed TG22/2
(TG2 KO) mice originally obtained from Gerry Melino49 and WT
inbred C57BL/6J mice as described before12 and in Supplemental
Material. A total of 32 WTand 32 TG2 KO mice were used, of which
16 per genotype were subjected to either UUO or sham operation.
Therefore, four groups of 16 mice were obtained: WT UUO, WT
Figure 9. Recruitment of TG2 in exosomes depends on SDC4. (A) EGFP-TG2–expressing NRK52E cells were treated with RNAi-
targeting SDC4 (SDC4 KO) or nontargeting RNAi (Scrbl. siRNA; used as a control). TLs were analyzed by Western blotting testing for
SDC4. (B) As a blotting control for SDC4, NRK52E cells were transiently transfected with HA-tagged SDC4 cDNA, and cell lysates were
blotted for HA. A mock transfection (2) was performed as a control. The arrow points at HA-tagged SDC4 with a molecular mass
between 25 and 35 kD. (C and D) Lysates of ectosome (P3) and exosome (P4) fractions isolated from the conditioned medium of SDC4
KO cells obtained as described in A and TLs were tested for (C and D) EGFP, (C) TG2, and (D) FLOT2. Intensity of immunoreactive
bands was quantiﬁed by densitometric analysis; graphs represent mean values 6SEM of (C) four (EGFP) or (D) three (FLOT2) in-
dependent experiments expressed relative to the scrambled nontargeting siRNA control (equalized to one). **P,0.01. (E) SDC4 was
immunoprecipitated from vesicular fractions and TLs with a rabbit polyclonal anti-SDC4 antibody. SDC4 immunoprecipitates were
analyzed by Western blotting for the presence of EGFP-TG2 (black arrowhead) and SDC4 (gray arrowheads).
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Figure 10. SDC4 KO leads to decreased TG2 membrane distribution and externalization ex vivo. Kidney glomeruli and tubules were
isolated from WT and SDC KO (SDC42/2) mice. Primary mesangial cells, ﬁbroblasts, and TECs were grown from glomeruli or tubules
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sham, TG2 KO UUO, and TG2 KO sham. The UUO and sham pro-
teome required lysate from one half of a kidney per animal and was
carried out in kidneys from fourmice per group. Kidneys were halved
longitudinally pole to pole through the papilla. Each one half was
then cut transversally to provide four identical quarters, with equal
cortex and medullary mass in each. The TG2 interactome required
two full organs per IP and was carried out in kidneys from 12 male
mice per group. Western blotting analysis required one quarter of
kidney per animal and was performed using kidneys from three male
mice per group as described before.8 Optimal size of biologic repli-
cates for the UUO and sham proteome analysis was determined by a
power calculation within Statistica software (Dell), and n=4 individ-
uals per treatment were sufﬁcient to power the experiment above
80%. In keeping with the principle of animal reduction, male and
female mice kidneys were used for general proteomics (one male and
three female). Linear regression analysis was performed on protein
peak areas after SWATH acquisition MS and conﬁrmed that the var-
iability in protein intensities produced by the male mice was not
higher than the intrinsic biologic variability detected among the fe-
male (P#0.05; mean standard residuals $5). All experimental pro-
cedures were carried out under license in accordance with regulations
laid down by Her Majesty’s Government, United Kingdom (Animals
Scientiﬁc Procedures Act ASPA, 1986), and they were approved by the
University of Shefﬁeld Animal Ethical ReviewCommittee (ASPA Eth-
ical Review Process) and the Nottingham Trent University Ethical
Review Committee (ASPA Ethical Review Process).
Fibrosis Measurement
The level of ﬁbrosis was assessed by Masson trichrome staining as
previously described.50
TGF-b Activity
The mink lung epithelial cell bioassay51 was performed as described
before.12,52
Isolation of TG2 Membrane Complexes and Data
Acquisition by MS
To isolate TG2-associated proteins from kidney fractions, 10% (wt/
vol) kidney homogenates were prepared from WTand TG2 KO kid-
neys, UUO and sham operated, by mechanical homogenization per-
formed on ice using an Ultra Turrax T25 homogenizer (Merck) in
homogenization buffer (0.25 M sucrose, 10 mM Tris-HCl, 1 mM
MgCl2, and 2mMEDTA, pH 7.4) containing protease inhibitor cock-
tail (Sigma-Aldrich). The whole homogenate was centrifuged at
10003g for 5 minutes at 4°C to remove larger particulates; then,
membranes were separated from the cytosolic fraction by centrifu-
gation at 20,0003g at 4°C for 30 minutes as previously described.12
The pellet (crude membrane fraction) was resuspended in IP buffer
(25 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% [vol/vol] NP40
detergent solution, and 5% [vol/vol] glycerol, pH 7.4) containing
protease inhibitor cocktail and membrane enrichment validated by
Western blotting. TG2 with associated proteins was immunoprecipi-
tated from the membrane fraction using the Pierce crosslink mag-
netic IP kit (Thermo Scientiﬁc) by protein A/G magnetic beads to
which anti-TG2 antibody (IA12; University of Shefﬁeld) was cross-
linked using disuccinimidyl suberate. Incubations of membrane ly-
sates with the antibody-coated beads were performed for 15 hours at
4°C in constant rotation. TG2-associated proteins were subjected to
trypsin digestion directly on the beads after washing the beads three
times with 50 mM ammonium acetate and incubating for 15 hours
with 200 ng/ml of proteomics-grade trypsin (Sigma-Aldrich) in
50 mM ammonium acetate. Peptides were analyzed by MS on re-
moval of the beads using a magnetic stand, by RP-HPLC-ESI-MS/
MS using a TripleTOF 5600+ mass spectrometer (SCIEX) in data-
dependent acquisition mode for spectral library construction, and in
SWATH 2.0 data-independent acquisition mode using static SWATH
acquisition windows for quantiﬁcation as described in Supplemental
Material. The MS proteomics data have been deposited in the Proteo-
meXchange Consortium (http://proteomecentral.proteomexchange.
org) via the PRIDE partner repository53 with the dataset identiﬁer
PXD008173. To deﬁne proteins signiﬁcantly associated with TG2, a z-
test statistical analysis was performed using TG2 IP from TG2 KO
kidney membranes as negative controls. Five independent TG2 IP
experiments were carried out, each on the basis of a lysate of two
kidneys. The obtained interactome has been submitted to the database
for CKD-related expression data CKDdb54 (http://www.padb.org/
ckddb/) with the dataset identiﬁer ExpGFEVabf79st4na.
The UUO Kidney Proteome
UUO and sham kidney halves were ground in liquid nitrogen, and a
10%(wt/vol) tissuehomogenatewasprepared in lysis buffer containing
9.5 M urea, 2% (wt/vol) dithiothreitol, 1% (wt/vol) N-octyl-
b-glucopyranoside, and protease inhibitors (Sigma-Aldrich)
with sonication. Equal amounts of total protein extracts (50 mg)
using selective growthmedium. (A) Extracellular TG activity wasmeasured by a well established assay in live cells (43104 cells per well of a
96-well plate) cultured on FN in the presence of the TG substrate biotin-cadaverine for 1 hour. Data represent mean Abs (450 nM)6SD of
three independent experiments undertaken in triplicates. (B) Total TG activity was similarly assayed but using whole cell lysate (60 mg per
well) and speciﬁc activities obtained from a standard curve of puriﬁed TG2. Data represent mean TG activity6SEM of three independent
experiments undertaken in triplicates. (C–E) TG2 was probed by Western blot using a mouse monoclonal anti-TG2 antibody (IA12) and
quantiﬁed by densitometric analysis on (C) cell membrane extracts, (D) cytosolic proteins, and (E) TLs. In each experiment, either Na+/K+
ATPase or b-tubulin was used as the loading control. Data represent mean intensities normalized for the loading control6SEM; n=3 per
group. (F) Extracellular TG activity was measured as described in A in WT and SDC4 KO (SDC42/2) primary TECs. Where indicated, SDC4
KO cells (SDC42/2) were transfected back with pcDNA3-hSdc4 plasmid or subjected to mock transfection (with transfection efﬁciency of
approximately 30%). Data represent mean Abs (450 nM) 6SEM; n=3 independent experiments undertaken in triplicates. *P,0.05;
**P,0.01; ***P,0.01.
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were diluted in 50 mM triethyl ammonium bi-
carbonate containing a ﬁnal concentration of
0.02% (wt/vol) ProteaseMAX surfactant (Prom-
ega). Proteins were subjected to reduction
(5 mM dithiothreitol at 56°C for 20 minutes)
and alkylation (15 mM iodoacetamide at room
temperature for 15 minutes), and then, they
were trypsin digested overnight at 37°C with
0.02 mg/ml MS-grade trypsin (Promega) and
0.01% (wt/vol) ProteaseMAX surfactant in a
thermomixer. Samples were vacuum concen-
trated to dryness and resuspended in 20 ml of
5% (vol/vol) acetonitrile/0.1% (vol/vol) formic
acid for MS analysis. SWATH data-independent
acquisition MS was performed on the obtained
peptides using variable SWATH windows. The
MS proteomics data have been deposited in the
ProteomeXchange Consortium (http://proteo-
mecentral.proteomexchange.org) via the PRIDE
partner repository53 with the dataset identiﬁer
PXD008173. Analysis of differentially expressed
proteins was performed using the OneOmics
cloud processing online platform (SCIEX) as de-
scribed in Supplemental Material. Proteome
data have been submitted to CKDdb54 (http://
www.padb.org/ckddb/) with the dataset identi-
ﬁer ExpGFEVyz6gt389dy.
Primary and Immortal Cell Lines
Tubules and glomeruli were isolated from
WT and SDC42 /2 (SDC4 KO)36 C57BL/6J
mice by perfusion of kidneys in situ with BSA-
inactivated Dynabeads and subsequent magnetic
separation, and they were cultured as previ-
ously described and detailed in Supplemental
Methods.55 Primary cortical TECs grew out
from tubules in selective medium with insulin,
transferrin, selenium, and EGF in 0.5% (vol/vol)
FBS to cause proliferation of just epithelial cells
and not ﬁbroblasts (grown out in medium with
10% FBS); primary mesangial cells were derived
from glomeruli in RPMI-1640 containing 20%
(vol/vol) FBS. Media composition is detailed in
Supplemental Material.
NRK52E rat renal proximal-like TECs and
NRK49F renal ﬁbroblasts were obtained from
the European Cell Culture Collection andmain-
tained in DMEM supplemented with 5% (vol/
vol) or 10% (vol/vol) heat-inactivated FBS, re-
spectively.
Plasmid Constructs and Transfections
The following constructs were prepared: pEGFP-
N1-TG2, where TG2 cDNAwas fused in frame to
the N terminus of EGFP in pEGFP-N1 plasmid
Figure 11. The proposed pathway of TG2 cell surface trafﬁcking in TEC during ﬁbrosis
progression involves TG2 targeting to exosomes from late endosomes by SDC4. TG2 is
secreted unconventionally by exosomes originating from late endosomes as multi-
vesicular bodies (MVBs), which then fuse with the PM, releasing the intraluminal vesicles
outside cells. (A) The biogenesis of TG2-bearing exosomes is mediated by ceramide,
because the inhibitor of N-SMase GW4869 signiﬁcantly reduces the presence of TG2 in
the exosome fraction. TG2, which has high afﬁnity for HS, is loaded on the surface of the
intraluminal vesicle as an HS/SDC4 cargo, and it is exposed on the surface of the formed
exosome. (B) After fusion of the outer membrane of MVB with PM, the TG2-bearing
exosomes likely accumulate in the ECM by TG2 binding to ECM/cell surface protein
partners in an “autocrine” or “paracrine” fashion. (C) After released with exosomes, TG2
could also undergo a conformational change and linearize because of the high Ca2+-to-
GTP ratio of the extracellular space, with a lowering or even loss of HS afﬁnity; the free
TG2 could bind the HS of other proteoglycans or other ECM partners. (D) In the matrix,
TG2 acts as an adhesive protein and matrix crosslinker, promoting ﬁbers accumulation
and latent TGF-b1 recruitment. (E) TG2 is also present in ectosomes. It is possible that
TG2, after it is secreted via exosomes, is captured by the PM and retained on ectosomes
shed by the PM. ER, endoplasmic reticulum.
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(Clontech), and pcDNA3.1(+)-hSdc4, where HA-Sdc4 cDNA (HA
downstream of the leader peptide provided by Mark Bass, Shefﬁeld
University) was subcloned frompBluescript in pcDNA3.1(+). All con-
structs were veriﬁed by Sanger sequencing. Cell transfection was per-
formed by TransIT (Mirus Bio). NRK52E was stably transfected with
pEGFP-N1-TG2 in medium supplemented with 700mg/ml G418, as
previously described,56 by using electroporation (Amaxa Nucleofec-
tor). SDC4 was knocked down by transient transfection with 100 nM
rat SDC4-targeting siRNA or scrambled control siRNA (Dharmacon;
Thermo Scientiﬁc) for 48 hours using DharmaFECT as transfection
reagent.
EV Isolation and Characterization
EVs were isolated from conditioned medium of cells by differential
centrifugation as described.24,25 Nanoparticle tracking analysis by tun-
able resistive pulse sensing was performed using qNano (Izon) to ex-
amine microparticle size and distribution. In some cases, cells were
stimulated by recombinant TGF-b1 (10 ng/ml) to simulate condi-
tions of ﬁbrogenesis in vitro. The EV inhibitor N,N9-Bis[4-(4,5-di-
hydro-1H-imidazol-2-yl)phenyl]-3,39-p-phenylene-bis-acrylamide
dihydrochloride, GW4869 (D1692; Sigma-Aldrich) was used as an
inhibitor of N-SMase57 and exosome biogenesis26 at a concentration
of 10 mM in serum-free medium for 16 hours. Amiloride hydrochlo-
ride (N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide hydro-
chloride hydrate; A7410; Sigma-Aldrich) was used at a concentration
of 1 mM for 10 minutes. For IPs from EV lysates, the Pierce crosslink
magnetic IP kit was used followed by Western blotting.
Detection of TG2 in Cell Fractions by Western Blotting
Cells were fractionated into membrane and cytosolic fractions, and
TG2 was detected as described before.12,13
Measurements of TG2 Activity at the Cell Surface of
Live Cells, in Cell Fractions, and in EVs
TG2 activity associatedwith the extracellular surface in cells in culture
and total TG2 activity in cell homogenates and fractions were assayed
by measuring the incorporation of biotin-cadaverine into FN by cal-
cium-dependent transamidation as previously described.13 EVs TG2
activity was measured in both EVs lysed in a sucrose-based buffer
(0.32 M sucrose, 5 mM Tris-HCl, and 2 mM EDTA, pH 7.4) with
protease inhibitor cocktail and intact EVs kept in suspension in sam-
ple buffer (Zedira) using the commercially available tissue transglu-
taminase picoassay kit (Zedira).
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